FDA warning letters target illegal online sales of opioids

FDA warning letters target illegal online sales of opioids

(HealthDay)—Four more online networks that operate 21 websites illegally selling potentially dangerous, unapproved, and misbranded versions of opioid pain medications have been told to immediately stop their sales, the U.S. Food and Drug Administration says. The order was made in warning letters sent to the networks.

"The illegal online sale of opioids represents a serious risk to Americans and is helping to fuel the crisis. Cutting off this flow of illicit internet traffic in opioids is critical, and we'll continue to pursue all means of enforcement to hinder online drug dealers and curb this dangerous practice," FDA Commissioner Scott Gottlieb, M.D., said in a statement. "Today's effort builds on previous actions against the illegal online sale of opioids, for a total of 13 warning letters to more than 70 websites just this summer."

Americans who buy prescription medicines such as opioids from illegal online pharmacies may be putting their health at risk because the drugs may be counterfeit, contaminated, expired, or otherwise unsafe, according to the FDA. Along with the health risks, consumers who use illegal online pharmacies face other threats, including , identity theft, and computer viruses.

The companies have 10 working days to respond to the warning letters. If they fail to correct the violations outlined in the letters, they may face legal enforcement action, the FDA said.


Explore further

FDA warns websites marketing unapproved opioids

More information: More Information

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA warning letters target illegal online sales of opioids (2018, August 29) retrieved 4 December 2020 from https://medicalxpress.com/news/2018-08-fda-letters-illegal-online-sales.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments